[go: up one dir, main page]

WO2002047659A2 - Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses - Google Patents

Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses Download PDF

Info

Publication number
WO2002047659A2
WO2002047659A2 PCT/US2001/051337 US0151337W WO0247659A2 WO 2002047659 A2 WO2002047659 A2 WO 2002047659A2 US 0151337 W US0151337 W US 0151337W WO 0247659 A2 WO0247659 A2 WO 0247659A2
Authority
WO
WIPO (PCT)
Prior art keywords
drug
aqueous solution
particles
organic mixture
drag
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/051337
Other languages
English (en)
Other versions
WO2002047659A3 (fr
Inventor
Keith P. Johnston
Robert O. Williams
Timothy J. Young
Xiaoxia Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Priority to AT01989339T priority Critical patent/ATE284676T1/de
Priority to EP01989339A priority patent/EP1335705B1/fr
Priority to AU2002243441A priority patent/AU2002243441A1/en
Priority to DE60107872T priority patent/DE60107872T2/de
Priority to CA002427625A priority patent/CA2427625A1/fr
Priority to JP2002549233A priority patent/JP2004515525A/ja
Publication of WO2002047659A2 publication Critical patent/WO2002047659A2/fr
Publication of WO2002047659A3 publication Critical patent/WO2002047659A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Definitions

  • the present invention relates to drug particles and methods for their preparation. More particularly, the present invention relates to the preparation of drug particles utilizing evaporative precipitation into aqueous solutions.
  • Bioavailability is a term meaning the degree to which a drug becomes available to the target tissue after being administered to the body. Poor bioavailability is a significant problem encountered in the development of pharmaceutical compositions, particularly those containing an active ingredient that is poorly soluble in water. Poorly water soluble drugs tend to be eliminated from the gastrointestinal tract before being absorbed into the circulation.
  • Spray drying into vapor is another method used to form micron sized drug particles. Spray drying is used commonly to formulate dry pharmaceutical powder. In most cases, either hydrophilic drugs in aqueous solution or poorly water soluble drugs in organic solution are sprayed, which approaches do not offer a means to simultaneously spray a poorly water soluble drug and water soluble excipient.
  • U.S. Patent No. 5,985,248 teaches dissolving a hydrophilic excipient, or stabilizer, and a hydrophobic drug in a cosolvent system such as water: ethanol, and spray drying the system into vapor.
  • U.S. Patent No. 6,001,336 teaches suspending a hydrophobic drug in an aqueous solution containing a hydrophilic stabilizer, and spray drying the suspension into vapor.
  • U.S. Patent No. 6,077,543 and WO 98/29096 teach atomizing an organic and an aqueous solution together into a vapor. In all of these teachings, drug particles in the micron size range are formed.
  • U.S. Patent Nos. 5,795,594 and 5,851,453 teach the use of compressed fluid antisolvents to form drug particles in the micron-size range.
  • This process has been called Precipitation using Compressed Antisolvents (PCA), Solution-Enhanced Dispersion of Solids (SEDS) and Supercritical AntiSolvent process (SAS).
  • PCA Compressed Antisolvents
  • SEDS Solution-Enhanced Dispersion of Solids
  • SAS Supercritical AntiSolvent process
  • this process does not utilize water due to the low solubility of water in compressed carbon dioxide, so that it is difficult to use water-soluble excipients with this process.
  • this process is able to use water by flowing an organic drug solution, an aqueous solution and a second organic solvent such as ethanol into compressed carbon dioxide. The ethanol is needed to extract the water into the CO2 phase.
  • Submicron Suspensions of Water-Insoluble Drugs Biotechnol. Prog. 2000, 16, 402-407, teach the formation of poorly water soluble drug particles by rapid expansion of supercritical fluid solutions into water.
  • the supercritical fluid was carbon dioxide above its critical temperature.
  • the solubility of drugs in carbon dioxide and other supercritical fluids such as ethane and propane is typically very small. It is difficult to add water soluble stabilizers and excipients in spray antisolvent processes (PCA, SAS or SEDS) into carbon dioxide due to the low solubility of water in CO2.
  • PCA spray antisolvent processes
  • the present invention is a method for preparing poorly water soluble drug particles comprising the steps of dissolving a drug in at least one organic solvent to form a drug/organic mixture; spraying the drug/organic mixture into an aqueous solution; and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles.
  • the present invention is poorly water soluble drag particles having an average particle diameter of from 50 nanometers to 20 microns, the drug particles being prepared by a process comprising the steps of dissolving the drug in at least one organic solvent to form a drug/organic mixture; spraying the drug/organic mixture into an aqueous solution; and concurrently evaporating the organic solvent in the presence of the aqueous solution to form an aqueous dispersion of the drug particles.
  • the present invention utilizes evaporative precipitation into aqueous solutions (EPAS) to form micron to sub-micron sized drag particles, leading to increased bioavailability relative to larger particles.
  • EPAS evaporative precipitation into aqueous solutions
  • the process of the present invention has applicability to a wide range of drug substances as several solvents may be chosen to dissolve the drug.
  • the ability to utilize poorly soluble drugs and water soluble stabilizers/excipients offers the ability to form submicron particles that have high dissolution rates in aqueous media.
  • the present invention also offers the ability to better control the resulting particle size and morphology relative to techniques described in the above identified prior art.
  • the present invention often produces particles having reduced crystallinity as compared to the bulk, unprocessed drug, which enhances dissolution.
  • Figure. 1 is a schematic diagram illustrating one embodiment of the process of the present invention.
  • Figure. 2 is a cross-sectional view of a vessel useful in the process of the present invention.
  • FIGS. 3-4 are graphs showing improved dissolution rates for particles of the present invention.
  • Figure. 5 is an SEM showing reduced crystallinity of the particles of the present invention.
  • Figure. 6 is a graph showing improved dissolution rates for particles of the present invention.
  • FIG. 1 is a schematic diagram illustrating one embodiment of an apparatus useful for the process of the present invention.
  • tank 11 contains a drug/organic mixture.
  • the drug/organic mixture is formed by dissolving a drag in at least one organic solvent.
  • the resulting drug/organic mixture can be a solution, an emulsion or a microemulsion.
  • the drug which can be used in the process of the present invention can be any poorly water soluble drag.
  • Suitable drug substances can be selected from a variety of known classes of drugs including, for example, analgesics, anti-inflammatory agents, anthelmintics, antianginal agents, anti-arrhythmic agents, antibiotics (including penicillins), anticoagulants, antidepressants, antidiabetic agents, antiepileptics, antigonadotropins, antihistamines, antihypertensive agents, antimuscarinic agents, antimycobacterial agents, antineoplastic agents, immunosuppressants, antithyroid agents, antiviral agents, anxiolytic sedatives (hypnotics and neuroleptics), astringents, beta-adrenoceptor blocking agents, blood products and substitutes, cardiacinotropic agents, contrast media, corticosterioids, cough suppressants (expectorants and mucolytics), diagnostic agents, diagnostic imaging agents, diuretics, dopaminergics (antiparkins
  • Preferred drag substances include those intended for oral administration and intravenous administration.
  • a description of these classes of drags and a listing of species within each class can be found in Martindale, The Extra Pharmacopoeia, Twenty-ninth Edition, The Pharmaceutical Press, London, 1989.
  • More specific examples of drug substances useful in the practice of the present invention include but are not limited to danazol, cyclosporine, nifedipine, carbamazepine, naproxen, triamcinolone and its salts, hydrocortisone and its salts, prednisone and its salts, phenylbutazone, betamethasone and its salts, dexamethasone and its salts, 17- ⁇ estradiol, ketoprofen, verapamil, ketoconazole, mefenamic acid, and metronidazole.
  • the organic solvent into which the drag is dissolved can be any organic solvent which dissolves the drug to an adequate level.
  • the organic solvent dissolves the drag to a level of 0.1 weight percent or more, and more preferably to a level of 1.0 weight percent or more.
  • the organic solvent is advantageously immiscible with water. Suitable organic solvents include diethylether, methylene chloride, ethyl acetate, dimethylether, perfluoroalkanes and isomers thereof, partially fluorinated solvents with or without other functional groups, and other organic solvents with boiling points below approximately 70° C, and combinations thereof.
  • the drag/organic mixture further contains a particle stabilizer.
  • Stabilization is defined herein to mean that the resulting drug particles do not grow substantially, and do not crystallize excessively.
  • a particle stabilizer is defined herein to mean a substance that substantially inhibits particle growth and substantially inhibits crystallization of the drug particles.
  • the particle stabilizer can be water soluble or organic soluble, although, if the particle stabilizer is water soluble, bioavailability may be enhanced to an even greater degree. Particle stabilizers can also act as absorption enhancers in order to increase bioavailability of the drug particles.
  • the particle stabilizer present in the organic can contribute to stabilization of the particle in the aqueous phase.
  • particle stabilizers include phospholipids, surfactants, either low molecular weight or polymeric, vesicles, polymers, including copolymers and homopolymers and biopolymers, and/or dispersion aids.
  • the particle stabilizer can be nonionic, anionic, cationic or zwitterionic.
  • Suitable surfactants include gelatin, casein, lecithin, (phosphatides), gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glyceryl monostearate, cetostearyl alcohol, cetomacrogol 1000, polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters, for example., the commercially available Tweens, polyethylene glycols, copolymers of polyethylene glycol and polypropylene glycol, polyoxyethylene stearates, colloidal silicon dioxide, phosphates, sodium dodecylsulfate, carboxymethlcellulose calcium, carboxymethylecellulose sodium, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinylalcohol, sodium lauryl sulfate (SLS), polyvinylpyrrol
  • the drug/organic mixture is fed through feed line 12 to a sprayer, where the drug/organic mixture is sprayed into an aqueous solution contained in tank 13.
  • the drug/organic mixture is sprayed at or below the liquid level of the aqueous solution in tank 13.
  • a portion of the aqueous solution can be sprayed together with the drag/organic mixture into the remaining portion of the aqueous solution.
  • the nozzle should be designed so as to allow the spraying of two streams simultaneously.
  • the level of the aqueous solution in tank 13 can be controlled by, for example, an overflow, such that a continuous slurry of particles results. The slurry of particles can then undergo further processing to result in the final drug particles.
  • Figure 2 is a cross-sectional view of tank 13 containing aqueous solution 21.
  • aqueous solution 21 contains at least one particle stabilizer. Suitable particle stabilizers include those listed above for inclusion in the drag/organic mixture.
  • the specific particle stabilizer or particle stabilizers selected for use in the aqueous solution 21 can be the same or can be different from the particle stabilizer(s) in the drag/organic mixture.
  • the weight ratio of drug to total particle stabilizer is from 0.01:1 to 10:1, preferably from 0.05:1 to 7:1 and more preferably from 0.1:1 to 4:1.
  • the drug/organic mixture is sprayed at or below the liquid level in tank 13 through atomizer 22 to form a jet comprising droplets 23.
  • the jet results in intense mixing between the drag/organic mixture droplets and the aqueous solution.
  • the organic solvent is concurrently evaporated into the aqueous solution 21 to form an aqueous dispersion of the drug particles.
  • Atomizer 22 can be any device that is capable of breaking up a bulk liquid into droplets. Suitable devices useful as atomizers include pressure nozzles, venturi nozzles, vibrating orifices, ultrasonic spray nozzles, rotating cups or disks, bubble caps or grids, or perforated plates.
  • the atomization of the evaporating organic solution into small droplets in the water and the intensity of the spray produce intense mixing between the growing drug particles and the water-soluble stabilizers and excipients.
  • the rapid evaporation of the organic solvent produces large supersaturation of the drag and rapid precipitation.
  • the rapid precipitation of the drug has the potential to produce amorphous instead of crystalline particles as the time frame is too short for crystallization.
  • the hydrophilic stabilizers remain solvated by water during the evaporation of the organic solvent. Thus, the stabilizers cover the growing drug particles and inhibit growth.
  • the morphology and particle size of the resulting particles may be controlled by varying the flow rate, nozzle geometry, concentration of drug and stabilizer and the nature of the stabilizer(s).
  • the temperature of the drug/organic mixture is at a level which allows for rapid evaporation of the solvent. Typically, this temperature will be at least 50 degrees centigrade (°C) below the normal boiling point of the organic solvent to 80°C above the normal boiling point of the organic solvent. If the temperature of the drag/organic mixture is at or above its normal boiling point, feed line 12 must be at sufficient pressure to maintain a liquid phase.
  • the temperature of the aqueous phase is preferably at least 10°C, more preferably at least 50°C, and even more preferably at least 70°C.
  • the upper temperature limit will depend upon the operating pressure, but is preferably low enough so as not to degrade the drug, but high enough to evaporate the solvent but not evaporate too much of the water.
  • the temperature is less than 120 °C, more preferably less than 95°C, and even more preferably less than 85°C.
  • the pressure of the aqueous solution can be at ambient pressure, below ambient pressure to facilitate evaporation or above ambient pressure.
  • the drug particles are produced in a liquid aqueous phase rather than a gas phase.
  • the particle growth is inhibited by aqueous stabilizers that do not precipitate.
  • the dissolution rates of the drug particles coated with water soluble stabilizers may be expected to be high since the dispersions come from an aqueous phase.
  • the particle formation stage is distinct from stage in which the aqueous solution is dried. Therefore the present invention can provide greater control over particle size.
  • the average particle diameter of the particles in the aqueous dispersion are from 50 nanometers to 20 microns, more preferably from 100 nanometers to 5 microns, and even more preferably from 200 nanometers to 1 micron.
  • the drag particles are not necessarily spherical. Average particle diameter can be measured using any technique known to those skilled in the art, such as sedimentation field flow fractionation, photon correlation spectroscopy, disk centrifugation or dynamic light scattering techniques.
  • An advantage of the present invention is the narrow polydispersity, also referred to as particle size distribution, that results.
  • the particle size distribution is typically monomodal, with narrow size ranges.
  • the process of the present invention desirably further comprises the step of recovering the drug particles.
  • recovering the drag particles comprises removing the water from the particles. Removing the water can be performed using any technique known to those skilled in the art, including spray drying, spray freeze drying, gellation, defined as gelling the particles within a polymeric matrix, lyophilization, drying with cold air, and filtration.
  • excipients can be added to either the drag/organic mixture or to the aqueous solution, either before or after the drag particles are formed, in order to enable the drug particles to be homogeneously admixed for appropriate administration.
  • Suitable excipients include polymers, absorption enhancers, solubility enhancing agents, dissolution rate enhancing agents, stability enhancing agents, bioadhesive agents, controlled release agents, flow aids and processing aids. More particularly, suitable excipients include cellulose ethers, acrylic acid polymers, and bile salts. Other suitable excipients are described in detail in the Handbook of Pharmaceutical Excipients, published jointly by the American Pharmaceutical Association and The Pharmaceutical Society of Great Britain, the Pharmaceutical Press, 1986. Such excipients are commercially available and/or can be prepared by techniques known in the art.
  • the apparatus shown in Figure 1 is used.
  • the drug/organic mixture was fed via a Constametric 3200 HPLC pump through a preheating coil into a 30 mL receiving tank containing the required amount of aqueous solution.
  • the nozzle used for the spraying was made by cutting 1/16" stainless steel tubing to form an elliptical conical geometry at the end. The end of the tube was filed to obtain the desired flow rate. Nitrogen was continuously flowed downward to break up foam in cases where it formed. For all of the examples, particle size was measured by dynamic light scattering techniques within 4 hours of the spray.
  • Dissolution testing for the following examples was carried out using a Nankel dissolution apparatus following the USP Apparatus II paddle method. During all dissolution tests, to ensure sink conditions, only 10-30 percent of the saturation solubility of the drug was added to the dissolution apparatus. The appropriate amount of final drug preparation was weighed and added to 900 ml of distilled water. Each sample was stirred at 50 rpm using a paddle-type stirrer. The dissolution apparatus was maintained at 37°C throughout the experiment. Samples in the amount of 5 ml were automatically withdrawn at 10, 20, 30 and 60 minute intervals. These samples were filtered using a 0.45 ⁇ m filter (Gelman GHP Acrodisc 0.45 ⁇ m, NWR).
  • the drag was cyclosporine, the organic was diethylether, and the concentration of the drag/organic mixture was 5.0 weight percent cyclosporine in diethylether.
  • aqueous solution Tween-80, a polyoxyethylene sorbitan monolaurate(ACROS) was a surfactant which was used as the particle stabilizer
  • ACROS polyoxyethylene sorbitan monolaurate
  • the drag was cyclosporine, the organic was diethylether, and the concentration of the drag/organic mixture was as shown below in Table B.
  • phosphatidyl choline (10 wt percent) a Sigma egg lecithin, 60 percent pure
  • the drag/organic mixture was sprayed into 10 mL aqueous solution at a rate of 1 ml/min.
  • the temperature of the aqueous solution is 75°C
  • the drag/organic mixture was sprayed into the aqueous solution at a temperature of 75°C.
  • Table B lists some processing parameters and the resulting particle sizes.
  • the drag was cyclosporine (5 wt percent), the organic solvent was that listed in Table C below.
  • Poloxamer 407 (1 wt percent), also known as Lutrol-F 127, a poly(ethylene)-poly(propylene) block polymer consisting of 73 percent of polyethylene glycol and 27 percent polypropylene glycol with an average molecular weight of 12,000 (BASF)
  • BASF a poly(ethylene)-poly(propylene) block polymer consisting of 73 percent of polyethylene glycol and 27 percent polypropylene glycol with an average molecular weight of 12,000 (BASF)
  • BASF average molecular weight of 12,000
  • the drug/organic mixture was sprayed into 25 mL aqueous solution at a rate of 1 ml/min. The temperatures of the aqueous solution and of the drag/organic mixture were 75°C. Table C lists some processing parameters and the resulting particle sizes.
  • the drag was danazol, and the solvent was methylene chloride.
  • the particle stabilizer in the aqueous solution is listed below in Table D. In all cases, the concentration of the particle stabilizer in aqueous solution was 1 weight percent.
  • the drug/organic mixture (2wt percent drug) was sprayed into the aqueous solution at a rate of 2 ml/minute for 5 minutes. The temperature of both the aqueous solution and the drug/organic mixture was 75°C. The drug/surfactant ratio was 1.06.
  • Myrj is polyoxyethylene monostearate.
  • the drag was Carbamazepine, and the solvent was methylene chloride.
  • the concentration of drug in the organic was 2 weight percent.
  • the particle stabilizer in the aqueous solution is listed below in Table E. In all cases, the concentration of the particle stabilizer in aqueous solution was 1 weight percent.
  • the drug/organic mixture was sprayed into the aqueous solution at a rate of 2.5 ml/min. The temperature of both the aqueous solution and the drug/organic mixture was 75 °C. The drug/surfactant ratio was 1:30.
  • the drug was Triamcinolone acetonide, also referred to herein as TAA, and the solvent was methylene chloride.
  • the concentration of drag in the organic was 0.5 weight percent.
  • the particle stabilizers in the aqueous solution and the organic solution are listed in Table F. In all cases the concentration of the particle stabilizer in the aqueous solution was 1 weight percent and in the organic solution was 0.5 weight percent. The volume of the aqueous solution was 15 ml.
  • the resulting aqueous drug suspension was poured into a hydroxypropylmethyl cellulose (HPMC) (grade E-5), thoroughly mixed by hand, poured into a glass crystallization dish and vacuum dried for at least 10 hours at temperatures ranging from 40-60°C and a vacuum level of 30 inches of Hg.
  • HPMC hydroxypropylmethyl cellulose
  • the resulting solids were mechanically ground to a powder and dissolution studies were performed on these powders. The results of these dissolution tests were compared with that for bulk TAA.
  • the results shown in Figure 3 indicate the increased dissolution rates of TAA processed according to the present invention.
  • the drug was carbamazepine and the solvent was methylene chloride.
  • the temperature of the drug/organic mixture and the receiving aqueous solution was 87°C.
  • the concentration of drug in the organic was 1.0 weight percent.
  • the particle stabilizers in the aqueous solution are listed in Table G. In all cases the concentration of the particle stabilizer in the aqueous solution was 2 weight percent and the organic solution contains, in addition to the drag, 0.5 weight percent Poloxamer 407.
  • the volume of the aqueous solution was 20 ml. In all cases the resulting aqueous drug suspension was sprayed into liquid nitrogen and the frozen particles were then lyophilized for 24 hours. The resulting powder was thoroughly mixed and dissolution studies were performed on these powders.
  • the drug was carbamazepine and the solvent was methylene chloride.
  • the temperature of the drug/organic mixture and the receiving aqueous solution was 87°C.
  • the concentration of drug in the organic was 1.0 weight percent.
  • the particle stabilizer in the aqueous solution was 2 weight percent deoxycholic acid and that in the organic solution was
  • the drug was nifedipine and the solvent was methylene chloride.
  • the concentration of drag in the organic was 1.0 weight percent.
  • the stabilizer in the aqueous solution was poly(vinyl alcohol) (PNA).
  • the volume of the aqueous solution was 20 ml.
  • Table H lists excipients added to the aqueous solution in addition to the PNA.
  • the resulting aqueous drug suspension was rapidly frozen by dipping the sample container in liquid nitrogen and then lyophilized for 24 hours. The resulting powder was thoroughly mixed and dissolution studies were performed on these powders. The results of these dissolution tests were compared with that for bulk nifedipine.
  • the drug was ketoprofen and the solvent was methylene chloride.
  • the temperature of the sprayed drag/organic mixture and the receiving aqueous solution was 87°C.
  • the concentration of drug in the organic was 1.0 weight percent.
  • the particle stabilizers in the aqueous solution are listed in Table J. In all cases the concentration of the particle stabilizer in the aqueous solution was 2 weight percent and the organic solution contains, in addition to the drug, 0.5 weight percent Poloxamer 407.
  • the volume of the aqueous solution was 20 ml. In all cases the resulting aqueous drag suspension was rapidly frozen by dipping the sample container in liquid nitrogen and then lyophilized for 24 hours. Crystallinity studies were performed on these powders using X-ray diffraction patterns, and were compared with that for bulk ketoprofen, which resulted in the processed powder exhibiting amorphous character as opposed to the bulk ketoprofen.

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

L'invention concerne un procédé de fabrication de particules de médicament faiblement solubles dans l'eau. Ce procédé consiste à dissoudre un médicament dans au moins un solvant organique afin de former un mélange médicament/organique, pulvériser ledit mélange médicament/organique dans une solution aqueuse et faire évaporer en même temps le solvant organique en présence de la solution aqueuse en vue de composer une dispersion aqueuse de particules de médicament. Les particules de médicament ainsi obtenues sont comprises dans la gamme de taille du nanomètre au micromètre et présentent de meilleures vitesses de dissolution et une cristallinité réduite lorsque l'on compare celle-ci à un médicament non traité.
PCT/US2001/051337 2000-11-03 2001-10-22 Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses Ceased WO2002047659A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AT01989339T ATE284676T1 (de) 2000-11-03 2001-10-22 Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
EP01989339A EP1335705B1 (fr) 2000-11-03 2001-10-22 Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses
AU2002243441A AU2002243441A1 (en) 2000-11-03 2001-10-22 Preparation of drug particles using evaporation precipitation into aqueous solutions
DE60107872T DE60107872T2 (de) 2000-11-03 2001-10-22 Herstellung von wirkstoffpartikeln durch evaporation-präzipitation in wässrige lösungen
CA002427625A CA2427625A1 (fr) 2000-11-03 2001-10-22 Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses
JP2002549233A JP2004515525A (ja) 2000-11-03 2001-10-22 水溶液中への蒸発沈降を用いた薬剤粒子の調製

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24547900P 2000-11-03 2000-11-03
US60/245,479 2000-11-03
US09/808,332 US6756062B2 (en) 2000-11-03 2001-03-14 Preparation of drug particles using evaporation precipitation into aqueous solutions
US09/808,332 2001-03-14

Publications (2)

Publication Number Publication Date
WO2002047659A2 true WO2002047659A2 (fr) 2002-06-20
WO2002047659A3 WO2002047659A3 (fr) 2002-09-06

Family

ID=26937266

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051337 Ceased WO2002047659A2 (fr) 2000-11-03 2001-10-22 Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses

Country Status (8)

Country Link
US (1) US6756062B2 (fr)
EP (1) EP1335705B1 (fr)
JP (1) JP2004515525A (fr)
AT (1) ATE284676T1 (fr)
AU (1) AU2002243441A1 (fr)
CA (1) CA2427625A1 (fr)
DE (1) DE60107872T2 (fr)
WO (1) WO2002047659A2 (fr)

Cited By (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006511461A (ja) * 2002-08-29 2006-04-06 ザ・コーポレーション・オブ・メイサー・ユニバーシティー マイクロカプセル化された物質及びそれらを作成する方法
JP4891773B2 (ja) * 2003-05-22 2012-03-07 アプライド ナノシステムズ ベー．フェー． 微小粒子の生成
US8551526B2 (en) 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US8906926B2 (en) 2008-12-29 2014-12-09 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8956656B2 (en) 2003-05-22 2015-02-17 Nano Fiber Matrices B.V. Production of small particles
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100031769A (ko) * 2000-12-28 2010-03-24 알투스 파마슈티컬스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
JP2005500304A (ja) * 2001-06-21 2005-01-06 アルタス バイオロジックス インコーポレイテッド 球状タンパク質粒子およびそれらの作製方法および使用方法
WO2003000226A2 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques contenant des ensembles polymere et medicament
ATE336231T1 (de) * 2001-08-29 2006-09-15 Dow Global Technologies Inc Verfahren zur herstellung kristalliner arzneimittelteilchen durch ausfällung
JP2007533647A (ja) * 2003-10-24 2007-11-22 アルザ・コーポレーシヨン 脂質粒子の調製
US7754243B2 (en) * 2004-08-03 2010-07-13 Clemson University Research Foundation Aqueous suspension of nanoscale drug particles from supercritical fluid processing
WO2006026502A1 (fr) * 2004-08-27 2006-03-09 The Dow Chemical Company Administration amelioree de compositions medicamenteuses pour le traitement d'infections parfois mortelles
WO2006116546A1 (fr) * 2005-04-27 2006-11-02 Baxter International Inc. Microparticules a surface modifiee et procedes de formation et d'utilisation associes
GB0613925D0 (en) * 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
JP2010505882A (ja) * 2006-10-06 2010-02-25 バクスター・インターナショナル・インコーポレイテッド 表面改質微粒子を含むマイクロエンカプセルならびに、その形成および使用の方法
US20100062073A1 (en) * 2006-11-29 2010-03-11 Ronald Arthur Beyerinck Pharmaceutical compositions comprising nanoparticles comprising enteric polymers casein
WO2008125940A2 (fr) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticules comprenant un médicament non cristallin
CN101292958B (zh) * 2007-04-27 2011-04-27 北京化工大学 一种超细达那唑粉体的制备方法
US20100080852A1 (en) * 2007-05-03 2010-04-01 Ronald Arthur Beyerinck Phamaceutical composition comprising nanoparticles and casein
WO2008135855A2 (fr) 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticules contenant un inhibiteur de la protéine de transfert d'ester de cholestéryle et un polymère non ionisable
WO2008135828A2 (fr) * 2007-05-03 2008-11-13 Pfizer Products Inc. Nanoparticules comprenant un médicament, de l'éthylcellulose et un sel biliaire
EP2162120B1 (fr) 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticules comportant un polymère cellulosique non ionisable et un copolymère bloc amphiphile non ionisable
WO2008149230A2 (fr) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticules comprenant un médicament, un polymère cellulosique non ionisable et du tocophéryl polyéthylène glycol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
US9724362B2 (en) 2007-12-06 2017-08-08 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
WO2009073216A1 (fr) * 2007-12-06 2009-06-11 Bend Research, Inc. Nanoparticules comprenant un polymère non ionisable et un copolymère de méthacrylate fonctionnalisé par amine
US20100151037A1 (en) * 2008-08-07 2010-06-17 Yivan Jiang Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
NZ720022A (en) 2010-03-12 2018-07-27 Berg Llc Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof
US20120141589A1 (en) * 2010-08-23 2012-06-07 Basf Se Particles for drug delivery and other applications
MY183615A (en) 2011-06-17 2021-03-03 Berg Llc Inhalable pharmaceutical compositions
WO2012178082A1 (fr) * 2011-06-24 2012-12-27 The Trustees Of Columbia University In The City Of New York Procédés, dispositifs et systèmes améliorés pour traiter des données de diffraction de rayons x
KR102047025B1 (ko) * 2019-05-07 2019-12-02 엔젯 주식회사 반도체 패키지의 언더필 방법 및 장치

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5766635A (en) * 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
GB9313650D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
JP5038552B2 (ja) * 1995-10-17 2012-10-03 オバン・エナジー・リミテッド 不溶性薬物の送達
AU6014098A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9801925B2 (en) 1999-06-29 2017-10-31 Mannkind Corporation Potentiation of glucose elimination
US8551526B2 (en) 2000-11-03 2013-10-08 Board Of Regents, The University Of Texas System Preparation of drug particles using evaporation precipitation into aqueous solutions
US9700690B2 (en) 2002-03-20 2017-07-11 Mannkind Corporation Inhalation apparatus
JP2006511461A (ja) * 2002-08-29 2006-04-06 ザ・コーポレーション・オブ・メイサー・ユニバーシティー マイクロカプセル化された物質及びそれらを作成する方法
JP4891773B2 (ja) * 2003-05-22 2012-03-07 アプライド ナノシステムズ ベー．フェー． 微小粒子の生成
US8956656B2 (en) 2003-05-22 2015-02-17 Nano Fiber Matrices B.V. Production of small particles
US9346766B2 (en) 2004-08-20 2016-05-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9796688B2 (en) 2004-08-20 2017-10-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
US9675674B2 (en) 2004-08-23 2017-06-13 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US10130685B2 (en) 2004-08-23 2018-11-20 Mannkind Corporation Diketopiperazine salts for drug delivery and related methods
US9283193B2 (en) 2005-09-14 2016-03-15 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US10143655B2 (en) 2005-09-14 2018-12-04 Mannkind Corporation Method of drug formulation
US9717689B2 (en) 2005-09-14 2017-08-01 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9446001B2 (en) 2005-09-14 2016-09-20 Mannkind Corporation Increasing drug affinity for crystalline microparticle surfaces
US9241903B2 (en) 2006-02-22 2016-01-26 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US10130581B2 (en) 2006-02-22 2018-11-20 Mannkind Corporation Method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9446133B2 (en) 2008-06-13 2016-09-20 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10751488B2 (en) 2008-06-13 2020-08-25 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10201672B2 (en) 2008-06-13 2019-02-12 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9339615B2 (en) 2008-06-13 2016-05-17 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9662461B2 (en) 2008-06-13 2017-05-30 Mannkind Corporation Dry powder drug delivery system and methods
US9511198B2 (en) 2008-06-13 2016-12-06 Mannkind Corporation Dry powder inhaler and system for drug delivery
US9192675B2 (en) 2008-06-13 2015-11-24 Mankind Corporation Dry powder inhaler and system for drug delivery
US12447293B2 (en) 2008-06-13 2025-10-21 Mannkind Corporation Dry powder inhaler and system for drug delivery
US10342938B2 (en) 2008-06-13 2019-07-09 Mannkind Corporation Dry powder drug delivery system
US9364619B2 (en) 2008-06-20 2016-06-14 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US10675421B2 (en) 2008-06-20 2020-06-09 Mannkind Corporation Interactive apparatus and method for real-time profiling of inhalation efforts
US9943571B2 (en) 2008-08-11 2018-04-17 Mannkind Corporation Use of ultrarapid acting insulin
US9220687B2 (en) 2008-12-29 2015-12-29 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9655850B2 (en) 2008-12-29 2017-05-23 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US8906926B2 (en) 2008-12-29 2014-12-09 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US10172850B2 (en) 2008-12-29 2019-01-08 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US9983108B2 (en) 2009-03-11 2018-05-29 Mannkind Corporation Apparatus, system and method for measuring resistance of an inhaler
US9630930B2 (en) 2009-06-12 2017-04-25 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US9706944B2 (en) 2009-11-03 2017-07-18 Mannkind Corporation Apparatus and method for simulating inhalation efforts
US10625034B2 (en) 2011-04-01 2020-04-21 Mannkind Corporation Blister package for pharmaceutical cartridges
US9364436B2 (en) 2011-06-17 2016-06-14 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10130709B2 (en) 2011-06-17 2018-11-20 Mannkind Corporation High capacity diketopiperazine microparticles and methods
US10258664B2 (en) 2011-10-24 2019-04-16 Mannkind Corporation Methods and compositions for treating pain
US9233159B2 (en) 2011-10-24 2016-01-12 Mannkind Corporation Methods and compositions for treating pain
US9610351B2 (en) 2011-10-24 2017-04-04 Mannkind Corporation Methods and compositions for treating pain
US10159644B2 (en) 2012-10-26 2018-12-25 Mannkind Corporation Inhalable vaccine compositions and methods
US10421729B2 (en) 2013-03-15 2019-09-24 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
US9925144B2 (en) 2013-07-18 2018-03-27 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler

Also Published As

Publication number Publication date
JP2004515525A (ja) 2004-05-27
EP1335705A2 (fr) 2003-08-20
CA2427625A1 (fr) 2002-06-20
WO2002047659A3 (fr) 2002-09-06
DE60107872T2 (de) 2005-05-19
AU2002243441A1 (en) 2002-06-24
EP1335705B1 (fr) 2004-12-15
US20020081334A1 (en) 2002-06-27
US6756062B2 (en) 2004-06-29
DE60107872D1 (de) 2005-01-20
ATE284676T1 (de) 2005-01-15

Similar Documents

Publication Publication Date Title
EP1335705B1 (fr) Preparation de particules de medicament au moyen de l'evaporation-precipitation dans des solutions aqueuses
US8551526B2 (en) Preparation of drug particles using evaporation precipitation into aqueous solutions
CA2458889C (fr) Procede de precipitation de particules medicamenteuses
US20120231093A1 (en) Method for preparing nano-scale or amorphous particle using solid fat as a solvent
Li et al. Process parameters and morphology in puerarin, phospholipids and their complex microparticles generation by supercritical antisolvent precipitation
CA2651346C (fr) Procede de preparation de nanoparticules de matiere active
KR20220163416A (ko) 생리 활성 물질이 균일하게 분산된 마이크로스피어 및 그것을 함유하는 서방성 제제
US7666307B2 (en) Particle size reduction of bioactive compounds
WO2003059319A1 (fr) Nanoparticules de medicament obtenues a partir d'emulsions matrices
CN115551550A (zh) 均匀分散有生理活性物质的微球及含有其的缓释制剂
AU2013206706B2 (en) Method for preparing nano-scale particle of active material
Williams III et al. Preparation of drug particles using evaporation precipitation into aqueous solutions
CN102836128B (zh) 制备水难溶或不溶药物的超细颗粒的方法
JP2007039430A (ja) 粒状物分散組成物及びその製造方法、並びに、粒状物及び医薬品
WO2007000842A1 (fr) Composition de dispersion de granules, procede de production de ceux-ci et materiau et medicament granulaire

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001989339

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2427625

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002549233

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2001989339

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 2001989339

Country of ref document: EP